CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 32 enrolled
Drug / intervention
Gemtuzumab Ozogamicindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04337138
NCT04337138N/ACompleted
CompareCT.gov

Characteristics, Treatment Patterns, and Clinical Outcomes in Acute Myeloid Leukemia (AML) Patients Using Mylotarg - a US Real-World Study Using Electronic Medical Record Data

Pfizer·observational·Posted Apr 7, 2020·Updated Aug 9, 2021

In Brief

An observational study evaluating Gemtuzumab Ozogamicin for Leukemia, Myeloid, Acute. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The aim of this observational study is to describe treatment patterns and effectiveness outcomes in a sample of oncology patients treated for AML with Mylotarg through up to two additional relapsed/refractory (R/R)-based lines of therapy (through third-line therapy). The study will use United States oncology electronic medical record (EMR) data. All study data are secondary data and will have been collected retrospectively from existing clinical data originally collected as part of routine care.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 7, 2020
Enrollment StartApr 7, 2020
Primary CompletionJul 31, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.2 years ago

Interventions

Gemtuzumab Ozogamicindrug

Gemtuzumab Ozogamicin (Mylotarg) administered in any form or combination